JP2020519675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519675A5 JP2020519675A5 JP2019563246A JP2019563246A JP2020519675A5 JP 2020519675 A5 JP2020519675 A5 JP 2020519675A5 JP 2019563246 A JP2019563246 A JP 2019563246A JP 2019563246 A JP2019563246 A JP 2019563246A JP 2020519675 A5 JP2020519675 A5 JP 2020519675A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- immunoconjugate
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023096307A JP2023113921A (ja) | 2017-05-16 | 2023-06-12 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ－１抗体の組み合わせ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506940P | 2017-05-16 | 2017-05-16 | |
| US62/506,940 | 2017-05-16 | ||
| US201762560462P | 2017-09-19 | 2017-09-19 | |
| US62/560,462 | 2017-09-19 | ||
| US201862647008P | 2018-03-23 | 2018-03-23 | |
| US62/647,008 | 2018-03-23 | ||
| PCT/US2018/032692 WO2018213260A1 (en) | 2017-05-16 | 2018-05-15 | Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096307A Division JP2023113921A (ja) | 2017-05-16 | 2023-06-12 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ－１抗体の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020519675A JP2020519675A (ja) | 2020-07-02 |
| JP2020519675A5 true JP2020519675A5 (enExample) | 2021-06-17 |
| JPWO2018213260A5 JPWO2018213260A5 (enExample) | 2022-05-18 |
Family
ID=64269828
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563246A Pending JP2020519675A (ja) | 2017-05-16 | 2018-05-15 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ−１抗体の組み合わせ |
| JP2023096307A Pending JP2023113921A (ja) | 2017-05-16 | 2023-06-12 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ－１抗体の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096307A Pending JP2023113921A (ja) | 2017-05-16 | 2023-06-12 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ－１抗体の組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20180333503A1 (enExample) |
| EP (1) | EP3625262A4 (enExample) |
| JP (2) | JP2020519675A (enExample) |
| KR (1) | KR20200006546A (enExample) |
| CN (2) | CN118078987A (enExample) |
| AU (1) | AU2018269173A1 (enExample) |
| BR (1) | BR112019023909A8 (enExample) |
| CA (1) | CA3063893A1 (enExample) |
| IL (1) | IL314823A (enExample) |
| MX (1) | MX2019013753A (enExample) |
| RU (1) | RU2019141270A (enExample) |
| TW (3) | TW202440170A (enExample) |
| WO (1) | WO2018213260A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| CN114441757A (zh) | 2011-04-01 | 2022-05-06 | 伊缪诺金公司 | 用于增加folr1癌症治疗的功效的方法 |
| CN115925952A (zh) | 2018-03-13 | 2023-04-07 | 东莞凡恩世生物医药有限公司 | 抗叶酸受体1抗体及其用途 |
| US20220047716A1 (en) * | 2018-09-17 | 2022-02-17 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
| EP3906415A1 (en) * | 2019-01-03 | 2021-11-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer |
| MX2023012557A (es) | 2021-04-23 | 2023-11-08 | King S College London | Composicion que comprende un anticuerpo ige. |
| TW202409080A (zh) * | 2022-07-26 | 2024-03-01 | 美商沙塔克實驗室股份有限公司 | 用於治療卵巢癌之組合療法 |
| CN115960269A (zh) * | 2023-01-30 | 2023-04-14 | 上海甲贝医药科技有限公司 | 一种重组长效人cxcr4&pd-1双靶点抗体融合蛋白及其制备方法 |
| CN120919340A (zh) * | 2024-05-09 | 2025-11-11 | 百奥泰生物制药股份有限公司 | 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用 |
| CN118684782A (zh) * | 2024-07-17 | 2024-09-24 | 武汉科技大学 | 一种muc16和folr1双靶点嵌合抗原受体dcar-16-r1及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5191537B2 (ja) * | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| TWI672318B (zh) * | 2010-02-24 | 2019-09-21 | 美商免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| KR102130865B1 (ko) * | 2012-10-02 | 2020-08-05 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하기 위한 항-kir 항체와 항-pd-1 항체의 조합물 |
| MY174670A (en) * | 2013-10-08 | 2020-05-06 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
| US20150297744A1 (en) * | 2014-03-28 | 2015-10-22 | Immunogen, Inc. | Anti-FOLR1 Immunoconjugate Dosing Regimens |
| RU2753902C2 (ru) * | 2014-11-20 | 2021-08-24 | Ф.Хоффманн-Ля Рош Аг | Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1 |
| EP3233918A1 (en) * | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| KR102700777B1 (ko) * | 2015-09-17 | 2024-08-29 | 이뮤노젠 아이엔씨 | 항-folr1 면역접합체를 포함하는 치료제 조합 |
-
2018
- 2018-05-15 RU RU2019141270A patent/RU2019141270A/ru unknown
- 2018-05-15 AU AU2018269173A patent/AU2018269173A1/en not_active Abandoned
- 2018-05-15 CA CA3063893A patent/CA3063893A1/en active Pending
- 2018-05-15 CN CN202410214686.8A patent/CN118078987A/zh active Pending
- 2018-05-15 US US15/979,989 patent/US20180333503A1/en not_active Abandoned
- 2018-05-15 KR KR1020197034686A patent/KR20200006546A/ko not_active Ceased
- 2018-05-15 MX MX2019013753A patent/MX2019013753A/es unknown
- 2018-05-15 EP EP18802195.0A patent/EP3625262A4/en not_active Withdrawn
- 2018-05-15 WO PCT/US2018/032692 patent/WO2018213260A1/en not_active Ceased
- 2018-05-15 JP JP2019563246A patent/JP2020519675A/ja active Pending
- 2018-05-15 CN CN201880032356.XA patent/CN110799535A/zh active Pending
- 2018-05-15 BR BR112019023909A patent/BR112019023909A8/pt unknown
- 2018-05-15 IL IL314823A patent/IL314823A/en unknown
- 2018-05-16 TW TW113100663A patent/TW202440170A/zh unknown
- 2018-05-16 TW TW111134010A patent/TW202322853A/zh unknown
- 2018-05-16 TW TW107116641A patent/TW201900221A/zh unknown
-
2021
- 2021-07-21 US US17/382,286 patent/US20220160889A1/en not_active Abandoned
-
2023
- 2023-06-12 JP JP2023096307A patent/JP2023113921A/ja active Pending
- 2023-10-18 US US18/489,292 patent/US20240299571A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519675A5 (enExample) | ||
| RU2019141270A (ru) | Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител | |
| JP6800853B2 (ja) | 抗ｃ１０ｏｒｆ５４抗体およびその使用 | |
| TWI795347B (zh) | 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌 | |
| JP2019031568A5 (enExample) | ||
| JP2018527383A5 (enExample) | ||
| JP2019500020A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| BR112020016986A2 (pt) | formulações de anticorpo contra b7-h4 | |
| US12324841B2 (en) | Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate | |
| US20250154250A1 (en) | Ceacam5 adc-anti-pd1/pd-l1 combination therapy | |
| CA3118542A1 (en) | Cdcp1-targeted therapies | |
| CA3091217A1 (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| KR20250160353A (ko) | 항-ceacam5 항체-약물 접합체, 항-vegfr-2 항체 및 항-pd1/pd-l1 항체를 함유하는 항종양 조합물 | |
| TW202228788A (zh) | 以結合191p4d12蛋白之抗體藥物結合物（adc）治療癌症之方法 | |
| JPWO2018213260A5 (enExample) | ||
| KR20250169564A (ko) | 암 치료법에서 환자 선택을 위한 CEACAM5 mRNA 검정 | |
| WO2024026019A1 (en) | Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies | |
| AU2022318734A1 (en) | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies | |
| RU2022129967A (ru) | Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител | |
| WO2026021442A1 (zh) | 抗体药物偶联物在制备治疗肺癌的药物中的用途 | |
| TWI912619B (zh) | 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌 | |
| WO2024213081A1 (zh) | 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途 | |
| WO2026026912A1 (zh) | 抗体药物偶联物和抗vegf抗体的联合应用 | |
| WO2025064741A1 (en) | Treating locally advanced or metastatic urothelial cancer with anti-191p4d12 antibody drug conjugates in combination with pembrolizumab |